BTIG Maintains Buy on Exagen, Raises Price Target to $9

Benzinga Newsdesk www.benzinga.com Positive 81.5%

Neg 0% Neu 0% Pos 81.5%

BTIG analyst Mark Massaro maintains Exagen (NASDAQ:XGN) with a Buy and raises the price target from $8 to $9.

Comments

No comments yet. Be the first!